(BW)(NY-PALL)(PLL)颇尔公司在国际细胞疗法会议上提交研究结果，这项技术能够更快更有效地完成细胞培植

商业编辑/健康/医疗作者

国际细胞疗法协会（International Society for Cellular Therapy，ISCT）

第20号展台

多媒体网址：

http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5140106

美国商业新闻2006年5月4日纽约州EAST HILLS消息——

一种新型工具点亮了再生药品的前景

分离与培植细胞是开发修复与置换患病组织与器官的关键性的第一步，新推出的一种过滤技术与传统技术相比能够更快更有效实现细胞分离。这项发现在今天已经被提交给在德国柏林举的国际细胞疗法协会(ISCT)年会上面。颇尔公司(Pall Corporation)（纽约证券交易所：PLL）过滤培植系统能够成为一款有价值的工具，来帮助实现再生药品的未来，科学家们相信这种工具在治疗心脏病、癌症、糖尿病、骨损伤以及其他急慢性疾病方面将能带来重大突破。

Pall Life Sciences细胞疗法研发总监Lisa Bradbury博士提交了颇尔公司的过滤培植系统与从全血中分离单核细胞(MNC)的传统的开放式浓度梯度离心分离方法之间的对比数据。颇尔公司的过滤培植系统能够大幅缩短处理时间；它能够在15分钟里完成分离，而与之相比，聚蔗糖(Ficoll)梯度技术的平均处理技术则在2.5小时至4个小时之间。过滤培植系统同时还能够分离出更多的单核细胞来，与聚蔗糖方法相比其提取率要高的多（高出60%至95%）。

颇尔公司的过滤培植系统能够用作采用了美国药品生产质量管理规范(cGMP)的封闭系统，从而能够进一步提高满足越来越严格的细胞产品安全、可再生与疗效规定要求的能力。除了快速处理之外，颇尔公司的系统能够使用时再运行（手术室）。其不需要增加额外的实验室设备以及另外培训技术人员，这种方法易于学习与使用。

Pall New Technologies高级副总裁Judy Angelbeck博士说道：“研究细胞疗法的研究人员与企业表示它们需要更好更方便的方法来分离与培植细胞，需要提高细胞提取率，加快处理时间与提高易用性，从而提高满足未来监管要求的可能性。颇尔公司在血液过滤方面长期处于领先位置，我们能够将我们在介质与细胞反应之间的材料科学专家经验进行转化，从而开发出这种新型细胞培植方法，”

颇尔公司的系统可以被用来利用包括周围血液、骨髓、脐带血液在内的多种生物试样中培植细胞。公司目前正在与几家企业合作来应用其过滤培植系统，从而来在包括整形术在内的多种治疗领域中开发创新的细胞疗法。

Angelbeck博士补充说道：“我们非常高兴颇尔公司的技术能在医药业的革命性进步中发挥重要作用，为从实验室到医院的研究人员提供实施新型细胞疗法所需的工具，这也是我们开发安全、简单的常规疗法的目标的一部分。”

包括细胞疗法在内的再生药品是一块富有前景的科研领域，其能够用来医治与治疗快速增加的各种疾病与创伤。科学家们相信细胞疗法能够在心脏病发作后修复受损的心肌，能够置换烧伤患者的皮肤，恢复脊髓损伤病人的移动能力以及帮助糖尿病人恢复能够生成胰岛素酶的胰腺组织。再生药品通过支持与激活人体的自然痊愈能力来改善健康与提高生活质量。

关于颇尔公司(Pall Corporation)

颇尔公司是快速发展的过滤、分离与纯化领域里的全球领导企业。颇尔公司的业务主要包括两大市场：生命科学与工业市场。公司提供先进的产品以满足生物工程、制药、输血、半导体、水净化、航天以及更多工业市场的需求。公司2005会计年度的总收入为19亿美元。公司总部位于纽约州East Hills，在全球各地设有众多的业务机构。了解关于Pall的更多信息，请访问网站 http://www.pall.com 。

编辑注释：

——请参观颇尔公司在德国柏林Maritim proArte旅馆(MaritimproArteHotel)举行的国际细胞疗法协会年会上设立的第20号展台。

——Bradbury博士将会在5月5日星期五18:00-20:00（下午6:00-8:00）举行的第31场讲座上宣讲其研究论文《一种从全血中快速分离单核细胞的封闭式过滤系统(A rapid closed filter-based system for mononuclear cell isolation from whole blood)》。她还会在5月7日星期天上午7:30-8:30在Salon 4就这项新技术提供指导。

——Bradbury博士和Angelbeck博士将会接受采访。

——网页 http://www.pall.com/corporate_39824.asp 提供新技术图片下载

——观看颇尔公司的过滤培植系统如何工作的动画以及了解关于Pall的再生药品与细胞疗法的更多信息，请访问网站 www.pall.com/celltherapy 。

*Ficoll是属于GE Healthcare Bio-Sciences所有商标。

多媒体网址：

http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5140106

联系方式：颇尔公司(Pall Corporation) 媒体联系： Marcia Katz，516-801-9851 Marcia_Katz@pall.com 或者 投资者关系部： Patricia Iannucci，516-801-9848 Pat_Iannucci@pall.com

(BW)(NY-PALL)(PLL) Pall Technology Enables Faster and More Efficient Cell Harvest, New Study Results Presented at International Cell Therapy Meeting

Business Editors/Health/Medical Writers

International Society for Cellular Therapy (ISCT)

Booth #20

MULTIMEDIA AVAILABLE:

http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5140106

EAST HILLS, N.Y.--(BUSINESS WIRE)--May 4, 2006--

A Novel Tool that Unleashes the Promise of Regenerative Medicine

A new, transformative filtration-based technology for the isolation and enrichment of cells, a critical first step in the development of therapies to repair or replace diseased or damaged tissues and organs, was found to be more efficient and faster than traditional technology used for cell separation. These findings were presented today at the International Society for Cellular Therapy (ISCT) annual meeting in Berlin, Germany. The Pall Corporation (NYSE:PLL) Filter Harvest System was found to have the potential to become a valuable tool to help realize the promise of regenerative medicine, a field that scientists believe could produce significant breakthroughs in the treatment of heart disease, cancer, diabetes, bone injury and many other acute and chronic conditions.

Lisa Bradbury, Ph.D., Director, R&D Cell Therapy, Pall Life Sciences, presented data comparing the Pall Filter Harvest System to a traditional open-system, density gradient, centrifuge-based method for isolation of mononuclear cells (MNC) from whole blood. The Pall Filter Harvest System was found to significantly reduce processing time; it can be performed in less than 15 minutes compared to an average processing time of about 2.5 to 4 hours with the Ficoll gradient technique. The Filter Harvest System also exhibited higher yield of MNCs for significantly better recovery (60 to 95 percent) than the Ficoll method.

The Pall Filter Harvest System can be used as a closed system that adheres to Good Manufacturing Practice (cGMP), furthering the ability to comply with increasingly stringent regulations for safe, reproducible and efficacious cell products. In addition to rapid processing, the Pall system can be performed at point of use (operating room). It does not require the addition of laboratory equipment or trained technicians, as the method is easy to learn and use.

"Researchers and companies working in cell therapy expressed the need to find better and easier ways to isolate and enrich cells that result in higher cell yield, faster processing time, ease of use and are also more likely to meet future regulatory requirements," stated Judy Angelbeck, Ph.D., senior vice president, Pall New Technologies. "Pall was able to translate its material science expertise on the interactions between media and cells based on our long-standing leadership in blood filtration to develop this new approach to cell harvesting."

The Pall system can be used to harvest cells from a broad range of biological samples including peripheral blood, bone marrow and umbilical cord blood. The Company is currently working with several companies in applying its filter harvest system to the development of innovative cell-based therapies in a variety of therapeutic areas, including orthopedics.

"We are pleased that Pall technology can play a key role in the revolutionary advances now occurring in medicine by providing researchers with the tools to take novel cell therapies from the laboratory into the clinic, as part of our goal to make cell therapy safe, routine and simple," Dr. Angelbeck added.

Regenerative medicine, which includes cell therapy, is a promising area of scientific research with application in the treatment and cure of a rapidly expanding list of diseases and injuries. Scientists believe cell-based therapies could be used to repair damaged heart muscle following a heart attack, replace skin for burn victims, restore movement after a spinal cord injury and regenerate pancreatic tissue to produce insulin for people with diabetes. Regenerative medicine promises to improve health and quality of life by supporting and activating the body's natural healing abilities.

About Pall Corporation

Pall Corporation is the global leader in the rapidly growing field of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, semiconductor, water purification, aerospace and broad industrial markets. Total revenues for fiscal 2005 were $1.9 billion. The Company headquarters are in East Hills, New York with extensive operations throughout the world. Visit Pall at www.pall.com.

Editor's Notes:

-- Visit Pall Booth #20 at the ISCT, Maritim proArte Hotel, Berlin, Germany.

-- Dr. Bradbury will present the research study "A rapid closed filter-based system for mononuclear cell isolation from whole blood," Poster Session #31 on Friday, May 5, 18:00 - 20:00 (6:00 - 8:00 pm). She will also present a tutorial on the new technology on Sunday, May 7, 7:30-8:30 a.m in Salon 4.

-- Drs. Bradbury and Angelbeck are available for interviews.

-- Photos of the new technology can be found on http://www.pall.com/corporate_39824.asp

-- Animation on how the Pall Filter Harvest System works and additional information on Pall's capabilities in regenerative medicine and cell therapy can be viewed at www.pall.com/celltherapy.

*Ficoll is a trademark of GE Healthcare Bio-Sciences.

MULTIMEDIA AVAILABLE:

http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5140106

CONTACT: Pall Corporation Media: Marcia Katz, 516-801-9851 Marcia_Katz@pall.com or Investor Relations: Patricia Iannucci, 516-801-9848 Pat_Iannucci@pall.com